Myosin Therapeutics, a Jupiter, FL-based biotechnology firm offering a platform for molecular entities, raised an undisclosed quantity in Seed funding.
The spherical was led by Mint12 Pharma, LLC, with participation from the College of Florida Ventures, DeepWork Capital, and the Florida Alternative Fund.
Based in 2020 by Drs. Courtney Miller, Patrick Griffin, and Theodore Kamenecka, Myosin Therapeutics is growing its lead compound, MT-125, to deal with glioblastoma, which is an aggressive type of mind most cancers with a 95% fatality price and restricted remedy choices obtainable. In early fashions, MT-125 has proven that it may well concurrently arrest most cancers cell division and migration, and subsequently might be a first-in-class remedy.
The corporate intends to make use of the funds to succeed in IND submitting for MT-125.
FinSMEs
15/03/2023
